Major depressive disorder

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Review, Data analysis, Liebowitz social anxiety scale, PIN, LSAS, NMDA, IND, Risk, Adult, Calendar, Nasal spray, PALISADE, Probenecid, Depression, Central nervous system disease, Food, Nasdaq, Research, Fear, Anxiety, PH94B, COVID-19, Neuron, MDD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Hallucination, SEC, Annual report, Brain, Social anxiety disorder, SAD, Safety, U.S. Securities and Exchange Commission, Time, Company, Grammatical mood, PH10, Clinical trial, Patient, OLS, Therapy, Drug discovery, Hamilton Rating Scale for Depression, Central nervous system, Major depressive disorder, Industry, Decision-making, CNS, FDA, Trial of the century, Pharmaceutical industry, Fine chemical, G&A, Ajda

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported financial results for its fiscal year 2023 second quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported financial results for its fiscal year 2023 second quarter ended September 30, 2022 and provided a corporate update.
  • During the past quarter, Vistagen achieved several important milestones to advance our CNS pipeline.
  • Vistagen anticipates topline results from this exploratory Phase 2A AjDA trial during the first quarter of calendar 2023.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to discuss its financial results for its second quarter fiscal year 2023 ended September 30, 2022 and provide a corporate update.

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Retrieved on: 
Monday, October 31, 2022
Mental Health, FDA, Health, Clinical Trials, General Health, Pharmaceutical, Safety, Immunization, Injection, Proline, Amyloid, Drug Quality and Security Act, Food, Inflammation, Brain, Securities Act of 1933, Investigational New Drug, Nature, Charles River Laboratories, U.S. Securities and Exchange Commission, Leukapheresis, Patient, Forward-looking statement, DC, Dementia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, IIA, Membrane, Immunotherapy, Securities Exchange Act of 1934, University, FDA, Bipolar disorder, IND, Post-traumatic stress disorder, Major depressive disorder, Risk, MDD, PTSD, Meningoencephalitis, Monocyte, Nasdaq, Lithium, Pharmaceutical industry, Vaccine

We are grateful to receive this timely, favorable response from the FDA to initiate a Phase I/IIA trial with ALZN002.

Key Points: 
  • We are grateful to receive this timely, favorable response from the FDA to initiate a Phase I/IIA trial with ALZN002.
  • We are advancing the process and expect that the first patient will be dosed in the first quarter of 2023.
  • ALZN002 is a proprietary active immunotherapy product, which means it is produced by each patients immune system.
  • The IND supports initial deployment of a Phase I/IIA clinical trial, ALZN002-01, a first-in-human, randomized, double-blind, placebo-controlled, parallel-group study.

Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event

Retrieved on: 
Thursday, October 27, 2022
MDD, Suicide, SCA, Central nervous system, Private Securities Litigation Reform Act, Agency, Nature, Company, Student, Program, Neuroscience, U.S. Securities and Exchange Commission, Sanfilippo syndrome, Policy, Agency for Healthcare Research and Quality, Ketamine, Annual report, Senior management, FDA, Therapy, Major depressive disorder, Brain, Spinocerebellar ataxia, CEO, Parkinson's disease, PTSD, World, Breakfast, Meanings of minor planet names: 8001–9000, Degenerative disease, Mental health, ASIB, Industry, COVID-19, Nasdaq, Trial of the century, Disorder, ALS, Amyotrophic lateral sclerosis, Depression, Science, Education, NEW, Writing, Post-traumatic stress disorder, Movement disorders, Risk, Music, CNS, Psychiatry, Safety, Pharmaceutical industry, Nightclub, Online shopping, Behavior, Patient

NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World's Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the 5th.

Key Points: 
  • -Seelos Senior Management will sponsor the Press Breakfast on Friday November 4th at 8:30am and take part in 2 panel discussions on Saturday November 5th.
  • Additionally, Seelos will participate in a panel discussion titled: Route of Administration Dose; Does Dissociation Correlate with Antidepressant/Analgesic Effects on Saturday, November 5th at 10:40am ET.
  • Wonderland Miami offers the psychedelic medicine industry a unique in-person convergence of business, science, music, and emerging technologies.
  • The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business.

Greenbrook TMS Announces Dates for Its Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, October 26, 2022
Mental Health, Health, Patient, Depression, Webcast, Investor relations, TMS, FDA, Transcranial magnetic stimulation, Major depressive disorder, Pharmaceutical industry

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Key Points: 
  • For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.
  • Following the live call, a replay will be available on the Investor Relations section of the Companys website, www.greenbrooktms.com/investors/events.htm
    Operating through 191 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 900,000 TMS treatments to over 25,000 patients struggling with depression.

Actinogen Medical (AGW): re-initation — Cognitive enhancer targeting key diseases

Retrieved on: 
Saturday, October 22, 2022
Traffic barrier, MDD, Patient, Major depressive disorder, Government budget balance, Research, Probability, Medicine, AD, CI, Plasma, Phase, RNPV, Xanadu, Medical device, Thomas Edison

Actinogen is targeting two CI indications: for patients with mild CI in the early stages of Alzheimers disease (AD), and for patients with major depressive disorder (MDD).

Key Points: 
  • Actinogen is targeting two CI indications: for patients with mild CI in the early stages of Alzheimers disease (AD), and for patients with major depressive disorder (MDD).
  • Actinogen plans to start the Phase IIb portion on XanaMIA in patients with biomarker-confirmed early AD in H1 CY23.
  • We value Actinogen at A$651m or A$0.36/share, based on a rNPV analysis largely driven by Xanamem for early AD.
  • We apply a 12.5% probability for CI in MDD reflecting the cognitive improvement already shown in healthy patients.

HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies

Retrieved on: 
Thursday, October 20, 2022
CRHR1, Time, Deutsche Bank, MDD, Patient, Depression, Program, Brain, Entrepreneurship, Mental health, Precision medicine, Sport, VC, Company, Ketamine, Health, Board, CEO, Mental, Safety, Real Madrid CF, Anxiety, GLOBE, Clinical trial, TRD, Director, Lists of diseases, Psychiatry, Treatment-resistant depression, Major depressive disorder, Security (finance), Pharmaceutical industry

MUNICH, Germany, Oct. 20, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage biopharma company pioneering precision psychiatry, today announced it has raised an additional EUR 14.3 million in a funding series, bringing the total capital raised to date to EUR 42.3 million.

Key Points: 
  • With this funding, we will advance the development of our personalized therapies to combat severe, unmet mental health challenges around the world.
  • That's why I have decided to support HMNC as an investor and be part of the precision psychiatry revolution.
  • HMNC Brain Health expects to complete a second closing of this round by end of March 2023.
  • HMNC Brain Health (HMNC Holding GmbH) is a clinical stage precision psychiatry biopharma company, pioneering the development of personalized therapies, powered by its AI platform and predictive companion diagnostics suite, bringing substantial therapeutic benefit to select patient populations suffering from mental health disorders.

Homewood Health introduces its Interventional Psychiatry Service (IPS)

Retrieved on: 
Wednesday, October 19, 2022
Admission, The Residence, Holiday, Schizophrenia, IPS, Patient, Jagoda, Depression, Transcranial magnetic stimulation, Mental health, Bipolar disorder, ECT, Psychiatry, Esketamine, Trauma, Nasal administration, Physician, Electroconvulsive therapy, Brain, OHIP, Major depressive disorder, Pharmaceutical industry, Medical imaging, Ketamine

GUELPH, ON, Oct. 19, 2022 /CNW/ - Homewood Health announces the launch of its Interventional Psychiatry Service (IPS), featuring cutting-edge treatment options for individuals suffering from treatment-resistant depression and other mental health conditions.

Key Points: 
  • GUELPH, ON, Oct. 19, 2022 /CNW/ - Homewood Health announces the launch of its Interventional Psychiatry Service (IPS), featuring cutting-edge treatment options for individuals suffering from treatment-resistant depression and other mental health conditions.
  • Interventional Psychiatry is an emerging subspecialty within Psychiatry that encompasses various neuromodulation treatments such as Electroconvulsive Therapy (ECT) and Repetitive Transcranial Magnetic Stimulation (rTMS), as well as novel psychopharmacological agents such as ketamine.
  • Homewood's IPS delivers on its pledge to consistently provide innovative approaches to mental health and addiction treatment, combining evidence-based treatments, measurement-based care, and Homewood's deep expertise in mental health.
  • Homewood Health is a Canadian leader in the development and delivery of national, evidence-based mental health, trauma, and addiction treatment and services since 1883.

Arrivo BioVentures Announces SP-624 Demonstrated Robust Efficacy in Females With Major Depressive Disorder in Phase 2 Study

Retrieved on: 
Monday, October 17, 2022
Other Health, Health, General Health, Women, Pharmaceutical, Mental Health, Other Science, Research, Consumer, Science, Clinical Trials, MDD, Sirtuin 6, Montgomery–Åsberg Depression Rating Scale, Patient, Major depressive disorder, Depression, Female, MADRS, Week, SIRT6, SDS, Pharmaceutical industry

Arrivo BioVentures today announced preliminary results from its SP-624-201 study, a randomized, placebo-controlled Phase 2 clinical trial of SP-624 in 319 patients with major depressive disorder (MDD).

Key Points: 
  • Arrivo BioVentures today announced preliminary results from its SP-624-201 study, a randomized, placebo-controlled Phase 2 clinical trial of SP-624 in 319 patients with major depressive disorder (MDD).
  • Females represented two-thirds of the patients enrolled in the study, with 205 female patients contributing to the efficacy results.
  • Study SP-624-201 was a multicenter, 4-week, double-blind, placebo-controlled, 2-arm safety and efficacy study in patients with MDD.
  • Patients entering the study were required to have failed on one antidepressant in the current depressive episode.

Global Depression Treatment Therapy Market Research and Forecast Report 2022-2028 Featuring Key Players - Eli Lilly and Co., Johnson & Johnson, Pfizer, Merck, H. Lundbeck, & F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Pharmaceutical, Health, Mental Health, Statistics, Suicide, Cyclothymia, Crime, Prevalence, Pfizer, Growth, Population, Tablet, CAGR, MDD, Johnson & Johnson, Depression, Merck & Co., Lists of diseases, Panic disorder, Geography, SSRI, Workload, Xanthine oxidase inhibitor, Serotonin, R, WHO, World, Lupinus, Selective serotonin reuptake inhibitor, Awareness, Obsessive–compulsive disorder, World Health Organization, Anxiety disorder, Sexual abuse, Femicide, Bulimia nervosa, Major depressive disorder, Eli Lilly and Company, OCD, Pharmaceutical industry, Oil, Anxiety

The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global depression treatment market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period of 2020-2027.
  • The rising prevalence of depression among the global population is the major factor driving the growth of the depression treatment market.
  • The global depression treatment market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market.

Janssen celebrates World Mental Health Day to raise awareness on the importance of timely diagnosis and treatment

Retrieved on: 
Monday, October 10, 2022
People, Suicide, Disease, Pleasure, Appetite, Industry, Diagnosis, Anger, Johnson & Johnson, Sadness, Agitation, Patient, Depression, World Mental Health Day, Neuroscience, Lists of diseases, Treatment, Restless, Disability, Irritability, Weight gain, Natural history, GLOBE, Depression (mood), Major depressive disorder, Pharmaceutical industry

Depression is a chronic, relapsing illness that affects an estimated 300 million people worldwide, according to the World Psychiatric Association Commission.

Key Points: 
  • Depression is a chronic, relapsing illness that affects an estimated 300 million people worldwide, according to the World Psychiatric Association Commission.
  • The commission describes depression as "one of the world's leading causes of preventable suffering and premature mortality" and labels it a neglected global health crisis.
  • It is important to learn to identify warning signs that indicate possible mental disorders such as sadness, agitation, restlessness, irritability and anger.
  • The presence of each of these symptoms is enough to affect the functional life of the patient as a whole.